Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Core Viewpoint - Puma Biotechnology will host a conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results, following the release of these results [1]. Company Overview - Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products to enhance cancer care [1]. - The company in-licensed the global development and commercialization rights to PB272 (neratinib) in 2011, which was approved by the FDA in 2017 for treating early stage HER2-overexpressed/amplified breast cancer [1]. - Neratinib is marketed in the U.S. as NERLYNX® and has received additional FDA approvals for various cancer treatments [1]. Recent Developments - In September 2022, Puma entered into an exclusive license agreement for the anti-cancer drug alisertib, focusing on small cell lung cancer and breast cancer [1]. - The company initiated a Phase II clinical trial for alisertib monotherapy in February 2024 and another trial in November 2024 for its combination with endocrine therapy [1]. - Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on December 19, 2025 [1].